We have numerous vaccines, but still no effective COVID treatments. Why not?

We have numerous vaccines, but still no effective COVID treatments. Why not?

Wall Street Journal | 
Nearly a year and a half into the pandemic, researchers are still struggling to find effective, easy-to-use drugs to treat ...
For decades, scientists struggled to find a treatment for one of the most common lung cancer mutations. Amgen has won US approval for the first drug targeting the KRAS variant

For decades, scientists struggled to find a treatment for one of the most common lung cancer mutations. Amgen has won US approval for the first drug targeting the KRAS variant

Wall Street Journal | 
[A new] drug, called Lumakras, was approved [May 28] to treat a portion of lung cancer patients with a particular ...
Long-time pharma rivals unite to fight a common enemy: COVID-19

Long-time pharma rivals unite to fight a common enemy: COVID-19

Wall Street Journal | 
In the age of Covid-19, old adversaries are uniting around a common enemy: the new coronavirus. Their nascent partnership is ...
coronavirus drugs

Infographic: From vaccines to drugs, chasing ‘silver bullets’ targeting the fast-moving coronavirus

Wall Street Journal | 
For drug companies, there is suddenly only one priority: the coronavirus. More than 140 experimental drug treatments and vaccines for ...

Can Myriad Genetics maintain hold on breast cancer tests two years after loss of patents?

Wall Street Journal | 
Myriad Genetics Inc., used a patent-protected monopoly to become one of the most successful and controversial DNA testing companies in the world ...
cancer ribbon

Myriad BRCA test Medicare reimbursement rate (and price?) cut

Wall Street Journal | 
Medicare reimbursement rates for a popular genetic breast cancer test will drop by half in the new year as a ...
glp menu logo outlined

Newsletter Subscription

* indicates required
Email Lists